《大行報告》瑞銀上調頤海國際(01579.HK)目標價至17元 評級「沽售」
瑞銀發表報告指,頤海國際(01579.HK)的2022年銷售按年增3.4%至61億元人民幣;淨利潤則跌3.2%至7.42億元人民幣,仍較市場預期高6%,主要是由於較預期強的營銷費用控制。管理層目標是今年錄得高於行業平均的增長。該行認為,集團的短期增長可見度仍然較低,因為其主要產品的潮流風險以及消費者對方便食品的家居需求較低,維持「沽售」評級,目標價由16元上調至17元。
該行表示,中期來看,集團仍需加大品牌投入,提高單品理論銷售上限。該行將2023及24財年的每股盈測上調15%至19%,料2023及24財年淨利潤分別為8.73億元人民幣及9.49億元人民幣。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.